CCA
EVLO

Catalyst Capital Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Catalyst Capital Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29
Closed -$7K – 552
2018
Q2 		$7K Buy
+29
New +$8.46K ﹤0.01% 413

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Catalyst Capital Advisors's EVLO Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2018, closing a stake of 29 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in EVLO in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 37 funds tracked by Wall St. Rank hold EVLO as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 29 Evelo Biosciences, Inc. Common Stock shares in Q3 2018, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $7K in Q2 2018.
  • 37 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.